Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Rhea-AI Summary
Exagen (Nasdaq: XGN) will release fourth quarter and full year 2025 financial results before market open on March 10, 2026. Management will host a live conference call and webcast to review results.
Details: the call with CEO John Aballi and CFO Jeff Black is at 8:30 a.m. ET / 5:30 a.m. PT; a live webcast and a recorded replay will be available via the company investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – XGN
In the Feb 24 session, XGN declined 0.27%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.1% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 11 | Investor conferences | Positive | -2.5% | Management participation in two New York investor conferences for updates and meetings. |
| Nov 04 | Q3 2025 earnings | Positive | -9.0% | Strong Q3 2025 revenue growth, higher gross margin, and improved adjusted EBITDA loss. |
| Oct 23 | Scientific abstracts | Positive | +1.4% | Acceptance of six ACR 2025 abstracts showcasing biomarkers and diagnostic research. |
| Oct 21 | Earnings date | Neutral | +0.5% | Announcement of Q3 2025 earnings release date and conference call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several instances where positive or constructive news, including strong Q3 2025 results, was followed by negative price reactions, indicating a tendency toward divergence between news tone and short-term trading.
Over the last few months, Exagen has mixed catalysts. It announced investor conference participation in November 2025, accepted six abstracts for ACR Convergence 2025 in October 2025, and provided notice of its Q3 2025 earnings date. Q3 2025 results on November 4, 2025 highlighted strong revenue growth and improved metrics, yet the stock fell afterward. Against this backdrop, the new Q4 and full-year 2025 earnings date continues a pattern of regular investor communication and clinical visibility.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast:
- U.S. dial-in: 877-407-0890
- International dial-in: +1 201-389-0918
- Webcast: Available via the Exagen investor relations website at investors.exagen.com
Replay: A telephone replay will be available until Tuesday, March 24, 2026:
- U.S. replay: 877-660-6853
- International replay: +1 201-612-7415
- Replay passcode: 13757484
- Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen investor relations website at investors.exagen.com
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Contact:
Tina Jacobsen
Exagen Inc.
ir@exagen.com
